Genomic analysis of high-risk smoldering multiple myeloma

被引:39
作者
Lopez-Corral, Lucia [2 ]
Victoria Mateos, Maria [2 ]
Corchete, Luis A. [2 ]
Eugenia Sarasquete, Maria [2 ]
de la Rubia, Javier [3 ]
de Arriba, Felipe [4 ]
Lahuerta, Juan-Jose [5 ]
Garcia-Sanz, Ramon [2 ]
San Miguel, Jesus F. [1 ,2 ]
Gutierrez, Norma C. [2 ]
机构
[1] Univ Hosp Salamanca, Dept Hematol, Serv Hematol, Salamanca 37007, Spain
[2] Univ Salamanca, Ctr Invest Canc IBMCC USAI CIC, E-37008 Salamanca, Spain
[3] Hosp La Fe, Serv Hematol, E-46009 Valencia, Spain
[4] Hosp Morales Meseguer, Serv Hematol, Murcia, Spain
[5] Hosp 12 Octubre, Serv Hematol, E-28041 Madrid, Spain
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2012年 / 97卷 / 09期
关键词
gene expression profile; SNP array; FISH; smoldering myeloma; MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; SNORNA U50; PROGRESSION; CANCER; THALIDOMIDE; PROGNOSIS; THERAPY; BONE;
D O I
10.3324/haematol.2011.060780
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Smoldering myeloma is an asymptomatic plasma cell dyscrasia with a heterogeneous propensity to progress to active myeloma. In order to investigate the biology of smoldering myeloma patients with high risk of progression, we analyzed the genomic characteristics by FISH, SNP-arrays and gene expression profile of a group of patients with high-risk smoldering myeloma included in a multicenter randomized trial. Chromosomal abnormalities detected by FISH and SNP-arrays at diagnosis were not associated to risk of progression to symptomatic myeloma. However, the overexpression of four SNORD genes (SNORD25, SNORD27, SNORD30 and SNORD31) was correlated with shorter time to progression (P<0.03). When plasma cells from high-risk smoldering patients who progressed to symptomatic myeloma were sequentially analyzed, newly acquired lesions together with an increase in the proportion of plasma cells carrying a given abnormality were observed. These findings suggest that gene expression profiling is a valuable technique to identify smoldering myeloma patients with high risk of progression. (Clinical Trials NCT00443235)
引用
收藏
页码:1439 / 1443
页数:5
相关论文
共 24 条
[1]   Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma [J].
Cesana, C ;
Klersy, C ;
Barbarano, L ;
Nosari, AM ;
Crugnola, M ;
Pungolino, E ;
Gargantini, L ;
Granata, S ;
Valentini, M ;
Morra, E .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1625-1634
[2]  
Dimopoulos MA, 2000, BLOOD, V96, P2037
[3]   RISK OF DISEASE PROGRESSION IN ASYMPTOMATIC MULTIPLE-MYELOMA [J].
DIMOPOULOS, MA ;
MOULOPOULOS, A ;
SMITH, T ;
DELASALLE, KB ;
ALEXANIAN, R .
AMERICAN JOURNAL OF MEDICINE, 1993, 94 (01) :57-61
[4]   Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma [J].
Dispenzieri, Angela ;
Kyle, Robert A. ;
Katzmann, Jerry A. ;
Therneau, Terry M. ;
Larson, Dirk ;
Benson, Joanne ;
Clark, Raynell J. ;
Melton, L. Joseph, III ;
Gertz, Morie A. ;
Kumar, Shaji K. ;
Fonseca, Rafael ;
Jelinek, Diane F. ;
Rajkumar, S. Vincent .
BLOOD, 2008, 111 (02) :785-789
[5]   SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer [J].
Dong, Xue-Yuan ;
Rodriguez, Carmen ;
Guo, Peng ;
Sun, Xiaodong ;
Talbot, Jeffrey T. ;
Zhou, Wei ;
Petros, John ;
Li, Qunna ;
Vessella, Robert L. ;
Kibel, Adam S. ;
Stevens, Victoria L. ;
Calle, Eugenia E. ;
Dong, Jin-Tang .
HUMAN MOLECULAR GENETICS, 2008, 17 (07) :1031-1042
[6]   Implication of snoRNA U50 in human breast cancer [J].
Dong, Xue-Yuan ;
Guo, Peng ;
Boyd, Jeff ;
Sun, Xiaodong ;
Li, Qunna ;
Zhou, Wei ;
Dong, Jin-Tang .
JOURNAL OF GENETICS AND GENOMICS, 2009, 36 (08) :447-454
[7]   Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation:: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis [J].
Gutierrez, N. C. ;
Castellanos, M. V. ;
Martin, M. L. ;
Mateos, M. V. ;
Hernandez, J. M. ;
Fernandez, M. ;
Carrera, D. ;
Rosinol, L. ;
Ribera, J. M. ;
Ojanguren, J. M. ;
Palomera, L. ;
Gardella, S. ;
Escoda, L. ;
Hernandez-Boluda, J. C. ;
Bello, J. L. ;
de la Rubia, J. ;
Lahuerta, J. J. ;
San Miguel, J. F. .
LEUKEMIA, 2007, 21 (01) :143-150
[8]  
HJORTH M, 1993, EUR J HAEMATOL, V50, P95
[9]  
IMWG, 2010, BRIT J HAEMATOL, V121, P749
[10]   Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management [J].
Kyle, R. A. ;
Durie, B. G. M. ;
Rajkumar, S. V. ;
Landgren, O. ;
Blade, J. ;
Merlini, G. ;
Kroeger, N. ;
Einsele, H. ;
Vesole, D. H. ;
Dimopoulos, M. ;
San Miguel, J. ;
Avet-Loiseau, H. ;
Hajek, R. ;
Chen, W. M. ;
Anderson, K. C. ;
Ludwig, H. ;
Sonneveld, P. ;
Pavlovsky, S. ;
Palumbo, A. ;
Richardson, P. G. ;
Barlogie, B. ;
Greipp, P. ;
Vescio, R. ;
Turesson, I. ;
Westin, J. ;
Boccadoro, M. .
LEUKEMIA, 2010, 24 (06) :1121-1127